Poster, Podium & Video Sessions
Presentation Authors: Carlos Muller-Arteaga*, Ourense, Spain, Jose Emilio Batista Miranda, Barcelona, Spain, Carmen Zubiaur, Ainara Rabade Ferreiro, Bilbao, Spain, Rafael El Khoury Moreno, Sevilla, Spain, Gonzalo Morales Solchaga, Alzira, Spain, Javier Casas Nebra, Lugo, Spain, Manuel Leva Vallejo, Cordoba, Spain, Oscar Gonzalez Garcia, Osuna, Spain, Salvador Arlandis-Guzman, Valencia, Spain, Carlos Errando-Smet, Barcelona, Spain
Introduction: Oxybutynin is a drug that has proven effective in the treatment of overactive bladder. With the oral presentation, a deterioration in cognitive function is described. The transdermal formulation has shown a decrease of the active metabolite of oxybutynin (N-DEO) involved in the onset of side effects.
Cognitive impairment of anticholinergic drugs are related to passage through the blood brain barrier and antagonism of M1 receptors in the central nervous system being the elderly population more susceptible.
Objective: To determine if there is impairment of cognitive function in elderly patients, between 65 and 80 years of age, treated with transdermal oxybutynin. As secondary objectives assessed the efficacy of the drug and adherence.
Methods: Observational, retrospective, multicenter study.
Patients diagnosed with overactive bladder who met the criteria for inclusion / exclusion were assessed at office and treatment was indicated with Oxybutynin transdermal according to routine clinical practice and recommendations for use according to data sheet. Specific questionnaires pathology (Bladder Self-Assestment questionnaire (BSAQ), Patient Perception Bladder Control (PPBC)), of Adherence (Morisky-Green Test) and Assessment of Cognitive function (Impaired Memory, Test, Clock Drawing test) at the start and in the follow-up visit at 4 weeks of treatment were administered.
Statistical analysis: Results were treated with relative frequency measurement. For continuous variables, central tendency measures were used for comparisons Student t test, Wilcoxon and Chi-square test was used. The level of statistical significance was set at <0.05
Results: A total of 70 patients were evaluable with an average age of 71.37 years, 71.4% were women, 51.4% with basic education and 70% come from the urban environment with an average BMI of 28.68. Impaired Memory, Test results before and after treatment showed no significant differences in any of the areas of assessment of cognitive function. Similarly, no differences were observed in the Drawing Clock Test. Regarding adherence to treatment was 84% with improvement in symptoms and the PPBC and BSAQ questionnaires.
Conclusions: In our study not impaired cognitive function in elderly patients with overactive bladder syndrome treated with transdermal oxybutynin was observed
Source Of Funding: None
Saturday, May 13
3:30 PM – 5:30 PM